問卷

TPIDB > Principal Investigator

Principal Investigator


Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital (在職)

Division of Rheumatology

Division of General Internal Medicine

更新時間:2023-09-19

顏正賢Yen, Jeng-Hsien
  • Principal Investigator
  • Clinical Trial Experience (year) 17 years 9 個月

篩選

List

27Cases

2023-06-16 - 2026-07-31

Phase III

Active
A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel- group study to evaluate the efficacy, safety, and tolerability of cenerimod in adult subjects with moderate-to-severe systemic lupus erythematosus (SLE) on top of background therapy
  • Condition/Disease

    moderate-to-severe systemic lupus erythematosus (SLE)

  • Test Drug

    tablet

Participate Sites
11Sites

Not yet recruiting1Sites

Recruiting10Sites

2010-03-01 - 2013-12-31

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2005-11-01 - 2007-12-31

Phase III

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2023-06-01 - 2026-06-08

Phase III

Active
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren’s Syndrome With Moderate-to-Severe Symptom State
  • Condition/Disease

    Sjögren’s Syndrome

  • Test Drug

    injection

Participate Sites
4Sites

Recruiting4Sites

2024-02-12 - 2026-06-01

Phase III

Active
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjogren's Syndrome With Moderate-to-Severe Symptom State
  • Condition/Disease

    Sjogren's Syndrome

  • Test Drug

    Dazodalibep

Participate Sites
5Sites

Recruiting5Sites

2025-09-01 - 2029-12-31

Phase III

Active
A Multicenter, Long-term, Randomized, Extension Study to Evaluate the Safety and Tolerability of Dazodalibep in Participants with Sjögren’s Syndrome (SS)
  • Condition/Disease

    Sjögren’s Syndrome (SS)

  • Test Drug

    Injection

Participate Sites
5Sites

Recruiting5Sites

2015-09-01 - 2018-12-31

Phase IV

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2010-06-01 - 2013-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Terminated12Sites

2006-03-01 - 2012-03-01

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Study ended4Sites

1 2 3